News
01-29-2016, 10:11 AM
Eisai Inc. announced today that the U.S. Food and Drug Administration approved Halaven (eribulin mesylate) Injection (0.5 mg per mL) for the treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen.
More... (http://www.news-medical.net/news/20160129/Eisais-Halaven-receives-FDA-approval-for-treatment-of-patients-with-metastatic-liposarcoma.aspx)
More... (http://www.news-medical.net/news/20160129/Eisais-Halaven-receives-FDA-approval-for-treatment-of-patients-with-metastatic-liposarcoma.aspx)